Larimar’s update on Friedreich’s ataxia drug derailed by allergic reactionsnews2025-09-29T15:13:21+00:00September 29th, 2025|Endpoints News|
Enanta’s RSV treatment fails Phase 2b study, but positives seen in subgroupsnews2025-09-29T15:07:30+00:00September 29th, 2025|Endpoints News|
Tourmaline attracted small bidding war before $1.4B sale to Novartisnews2025-09-29T14:32:55+00:00September 29th, 2025|Endpoints News|
IO Biotech to run another study for cancer vaccine; Boehringer ends mid-stage IPF trial news2025-09-29T14:24:07+00:00September 29th, 2025|Endpoints News|
Mental health platform Wysa acquires physical therapy startup Kinsnews2025-09-29T13:00:44+00:00September 29th, 2025|Endpoints News|
A pivotal miss in hidradenitis suppurativa leaves MoonLake adriftnews2025-09-29T11:14:29+00:00September 29th, 2025|Endpoints News|
Genmab to buy Merus for $8B, with multibillion-dollar plans in head and neck cancernews2025-09-29T10:52:41+00:00September 29th, 2025|Endpoints News|
GSK names new CEO as Luke Miels will take Emma Walmsley’s spot on Jan. 1news2025-09-29T10:38:17+00:00September 29th, 2025|Endpoints News|
AstraZeneca plans direct New York listing in another blow to UK life sciencesnews2025-09-29T10:34:17+00:00September 29th, 2025|Endpoints News|
Pfizer’s GLP-1 acquisition; Trump’s tariff threat; Scholar Rock gets a CRL; and morenews2025-09-27T10:00:08+00:00September 27th, 2025|Endpoints News|
